Biotech News
Related news
ABUSArbutus2026-10-01 11:30 EST
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
ABUSArbutus2026-08-24 11:30 EST
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
AVIRAtea2026-11-09 12:00 EST
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
SPROSpero Therapeutics2026-11-10 13:00 EST
Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of Directors
Arbutus
Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins,...
Recent company news
ABUSArbutus2026-11-10 12:30 EST
Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update
ABUSArbutus2026-10-22 11:30 EST
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
ABUSArbutus2026-10-01 11:30 EST
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
ABUSArbutus2026-09-30 11:30 EST
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
ABUSArbutus2026-08-24 11:30 EST
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Stock data
- Close
- 4.07 USD
- Market cap
- 841.51M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
